Purpose of the document
The proposed attributes and criteria provide considerations for the evaluation and prioritization of COVID-19 candidate vaccines to be considered for further development by WHO. The target audience includes vaccine scientists, product developers, manufacturers, regulators and funding agencies.
The attribute and criteria below lay out some of the considerations that structure WHO’s case-by-case assessments of COVID-19 vaccines in the future, with emphasis on prioritization for Phase IIb/III evaluation.
Criteria that are considered of major importance in ranking the vaccines are reported in bold in the table. WHO will also provide a scoring guide to promote consistency and predictability of evaluation.
Vaccine prioritization for WHO Phase IIb/III clinical trial (PDF, 376 KB)
